



GlaxoSmithKline Consumer  
Healthcare Pakistan Limited  
35-Dockyard Road,  
West Wharf,  
Karachi - 74000,  
Pakistan

UAN +92 21 111 475 725  
Fax +92 21 3231 4898  
www.gsk.com.pk

September 07, 2018

**The General Manager  
Pakistan Stock Exchange Limited  
Stock Exchange Building  
Stock Exchange Road  
Karachi**

**SUBJECT: DISCLOSURE OF MATERIAL INFORMATION**

Dear Sirs,

In accordance with Sections 96 and 131 of the Securities Act, 2015 and Clause 5.19.13(c) of the Rule Book of the Pakistan Stock Exchange Limited, we hereby convey the following:

Pursuant to the approval of the Board of Directors of GlaxoSmithKline Consumer Healthcare Pakistan Limited ("**Company**") in the meeting held on June 05<sup>th</sup>, 2018 and in accordance with the Section 279 to Section 283 of Companies Act of 2017, the Company has filed a merger petition in the Hon'ble High Court of Sindh.

A disclosure form as required under S.R.O. 143(1)/2012 dated December 5, 2012 read with Section 131 of the Securities Act, 2015 is also enclosed as Annexure A.

Yours Faithfully,

**Mehar Ameer  
Company Secretary**

Copy: Commissioner, Company Law Division  
Securities and Exchange Commission of Pakistan  
NIC Building, Jinnah Avenue,  
Blue Area, Islamabad.



**ANNEXURE A**  
**DISCLOSURE FORM**  
**IN TERMS OF SECTIONS 96 AND 131 OF THE SECURITIES ACT, 2015**

<b>Name of Company:</b>	GlaxoSmithKline Consumer Healthcare Pakistan Limited 35 Dockyard Road, West Wharf, Karachi 74000 - Pakistan
<b>Date of Report:</b>	September 06, 2018
<b>Contact Information:</b>	Mehar Ameer Company Secretary 35 Dockyard Road, West Wharf, Karachi 74000 – Pakistan.  Telephone: +92 (21) 3520 2083 Fax Number: +92 21 3220 1386 - UAN: 111 475 725 Email Address: <a href="mailto:mehar.x.ameer@gsk.com">mehar.x.ameer@gsk.com</a>

Please mark the appropriate box below (see general Instructions A.1 below before filling the details).

Disclosure of inside information by listed company in terms of Section 15 D (1).

Public disclosure of inside information, which directly concerns the listed securities

Pursuant to the approval of the Board of Directors of the Company in the meeting held on June 05<sup>th</sup>, 2018 and in accordance with the Section 279 to Section 283 of Companies Act of 2017 the Company has filed a merger petition in the Hon'ble High Court of Sindh.

The Company has duly caused this form / statement to be signed / on its behalf by the undersigned hereunto duly authorized.

  
**Mehar Ameer**  
**Company Secretary**  
**Dated: September 07, 2018**